EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel Leptin-Based Therapeutic Strategies to Limit Synaptic Dysfunction in Alzheimer’s Disease

Jenni Harvey iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25137352 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jenni Harvey. Beteiligte Einrichtung: Department of Neuroscience, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK. Hauptthemen laut MEDLINE: Alzheimer Disease, Leptin, Synapses. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Society, Alzheimer’s Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accumulation of hyper-phosphorylated tau and amyloid beta (Aβ) are key pathological hallmarks of Alzheimer’s disease (AD). Increasing evidence indicates that in the early pre-clinical stages of AD, phosphorylation and build-up of tau drives impairments in hippocampal excitatory synaptic function, which ultimately leads to cognitive deficits. Consequently, limiting tau-related synaptic abnormalities may have beneficial effects in AD. There is now significant evidence that the hippocampus is an important brain target for the endocrine hormone leptin and that leptin has pro-cognitive properties, as activation of synaptic leptin receptors markedly influences higher cognitive processes including learning and memory. Clinical studies have identified a link between the circulating leptin levels and the risk of AD, such that AD risk is elevated when leptin levels fall outwith the physiological range. This has fuelled interest in targeting the leptin system therapeutically. Accumulating evidence supports this possibility, as numerous studies have shown that leptin has protective effects in a variety of models of AD. Recent findings have demonstrated that leptin has beneficial effects in the preclinical stages of AD, as leptin prevents the early synaptic impairments driven by tau protein and amyloid β. Here we review recent findings that implicate the leptin system as a potential novel therapeutic target in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseLeptinSynapsesHumansAnimalsAmyloid beta-Peptidestau ProteinsReceptors, LeptinHippocampus

Stichwörter der Autor:innen

AMPAhippocampusleptinreceptor traffickingsynaptic plasticitytau

Substanzen

LeptinAmyloid beta-Peptidestau ProteinsReceptors, Leptin

Autor:innen und Institutionen

  • Department of Neuroscience, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK.

ORCID-Profile: Jenni Harvey

Förderung

  • Alzheimer's Society
  • Alzheimer’s Society

Zitieren

APA

Harvey, J. (2024). Novel Leptin-Based Therapeutic Strategies to Limit Synaptic Dysfunction in Alzheimer’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137352

Vancouver

Harvey J. Novel Leptin-Based Therapeutic Strategies to Limit Synaptic Dysfunction in Alzheimer’s Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137352

BibTeX
@article{Harvey2024,
  author = {Harvey, Jenni},
  title = {Novel Leptin-Based Therapeutic Strategies to Limit Synaptic Dysfunction in Alzheimer’s Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25137352}
}
Kostenlos starten →